Th2 cell clonal expansion at diagnosis in human type 1 diabetes
Narsale A, Almanza F, Tran T, Lam B, Seo D, Vu A, Long SA, Cooney L, Serti E, Davies JD
Associated Clinical Trial(s):
Narsale A, Almanza F, Tran T, Lam B, Seo D, Vu A, Long SA, Cooney L, Serti E, Davies JD (2023). Th2 cell clonal expansion at diagnosis in human type 1 diabetes. Clin Immunol, 257, 109829. https://doi.org/10.1016/j.clim.2023.109829 PMID: 37907122.
Islet-autoreactive CD4+ T cells are linked with response to alefacept in type 1 diabetes
Balmas E, Chen J, Hu AK, DeBerg HA, Rosasco MG, Gersuk VH, Serti E, Speake C, Greenbaum CJ, Nepom GT, Linsley PS, Cerosaletti K
Associated Clinical Trial(s):
Balmas E, Chen J, Hu AK, DeBerg HA, Rosasco MG, Gersuk VH, Serti E, Speake C, Greenbaum CJ, Nepom GT, Linsley PS, Cerosaletti K (2023). Islet-autoreactive CD4+ T cells are linked with response to alefacept in type 1 diabetes. JCI Insight, 8(21). https://doi.org/10.1172/jci.insight.167881 PMID: 37751304. PMCID: PMC10721267.
Next-generation pathology detection of T cell-antigen-presenting cell immune synapses in human liver allografts
Wood-Trageser MA, Lesniak D, Gambella A, Golnoski K, Feng S, Bucuvalas J, Sanchez-Fueyo A, Demetris AJ
Associated Clinical Trial(s):
Wood-Trageser MA, Lesniak D, Gambella A, Golnoski K, Feng S, Bucuvalas J, Sanchez-Fueyo A, Demetris AJ (2023). Next-generation pathology detection of T cell-antigen-presenting cell immune synapses in human liver allografts. Hepatology, 77(2), 355-366. https://doi.org/10.1002/hep.32666 PMID: 35819312. PMCID: PMC9834436.
Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses
Duan M, Nguyen DC, Joyner CJ, Saney CL, Tipton CM, Andrews J, Lonial S, Kim C, Hentenaar I, Kosters A, Ghosn E, Jackson A, Knechtle S, Maruthamuthu S, Chandran S, Martin T, Rajalingam R, Vincenti F, Breeden C, Sanz I, Gibson G, Lee FE
Associated Clinical Trial(s):
Duan M, Nguyen DC, Joyner CJ, Saney CL, Tipton CM, Andrews J, Lonial S, Kim C, Hentenaar I, Kosters A, Ghosn E, Jackson A, Knechtle S, Maruthamuthu S, Chandran S, Martin T, Rajalingam R, Vincenti F, Breeden C, Sanz I, Gibson G, Lee FE (2023). Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses. Cell Rep, 42(7), 112682. https://doi.org/10.1016/j.celrep.2023.112682 PMID: 37355988. PMCID: PMC10391632.
Meeting Report: The Fifth International Samuel Strober Workshop on Clinical Immune Tolerance
Sykes M, Chandran S, Kawai T, Levitsky J, Mapara M, Mathew J, Thomson A, Yamada K
Associated Clinical Trial(s):
Sykes M, Chandran S, Kawai T, Levitsky J, Mapara M, Mathew J, Thomson A, Yamada K (2023). Meeting Report: The Fifth International Samuel Strober Workshop on Clinical Immune Tolerance. Transplantation, 107(3), 564-569. https://doi.org/10.1097/TP.0000000000004473 PMID: 36808845.
Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission
Gamerith G, Mildner F, Merkel PA, Harris K, Cooney L, Lim N, Spiera R, Seo P, Langford CA, Hoffman GS, St Clair EW, Fervenza FC, Monach P, Ytterberg SR, Geetha D, Amann A, Wolf D, Specks U, Stone JH, Kronbichler A
Associated Clinical Trial(s):
Gamerith G, Mildner F, Merkel PA, Harris K, Cooney L, Lim N, Spiera R, Seo P, Langford CA, Hoffman GS, St Clair EW, Fervenza FC, Monach P, Ytterberg SR, Geetha D, Amann A, Wolf D, Specks U, Stone JH, Kronbichler A (2023). Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission. Ann Rheum Dis, 82(2), 253-261. https://doi.org/10.1136/ard-2022-222479 PMID: 35973802.
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial
Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC, Type 1 Diabetes TrialNet Study Group
Associated Clinical Trial(s):
Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC, Type 1 Diabetes TrialNet Study Group (2023). Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care, 46(5), 1005-1013. https://doi.org/10.2337/dc22-2200 PMID: 36920087. PMCID: PMC10154649.
Risk factors for serious infections in ANCA-associated vasculitis
Odler B, Riedl R, Gauckler P, Shin JI, Leierer J, Merkel PA, St Clair W, Fervenza F, Geetha D, Monach P, Jayne D, Smith RM, Rosenkranz A, Specks U, Stone JH, Kronbichler A, RAVE−ITN Research Group
Associated Clinical Trial(s):
Odler B, Riedl R, Gauckler P, Shin JI, Leierer J, Merkel PA, St Clair W, Fervenza F, Geetha D, Monach P, Jayne D, Smith RM, Rosenkranz A, Specks U, Stone JH, Kronbichler A, RAVE−ITN Research Group (2023). Risk factors for serious infections in ANCA-associated vasculitis. Ann Rheum Dis, 82(5), 681-687. https://doi.org/10.1136/ard-2022-223401 PMID: 36702528. PMCID: PMC10176387.
Activation of a Latent Epitope Causing Differential Binding of Antineutrophil Cytoplasmic Antibodies to Proteinase 3
Casal Moura M, Thompson GE, Nelson DR, Fussner LA, Hummel AM, Jenne DE, Emerling D, Fervenza FC, Kallenberg CGM, Langford CA, McCune WJ, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Ytterberg SR, Stone JH, Robinson WH, Specks U, WGET and RAVE-ITN Research Groups
Associated Clinical Trial(s):
Casal Moura M, Thompson GE, Nelson DR, Fussner LA, Hummel AM, Jenne DE, Emerling D, Fervenza FC, Kallenberg CGM, Langford CA, McCune WJ, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Ytterberg SR, Stone JH, Robinson WH, Specks U, WGET and RAVE-ITN Research Groups (2023). Activation of a Latent Epitope Causing Differential Binding of Antineutrophil Cytoplasmic Antibodies to Proteinase 3. Arthritis Rheumatol, 75(5), 748-759. https://doi.org/10.1002/art.42418 PMID: 36515151. PMCID: PMC10191989.
Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Berti A, Hillion S, Konig MF, Moura MC, Hummel AM, Carmona E, Peikert T, Fervenza FC, Kallenberg CGM, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, Brunetta P, St Clair EW, Harris KM, Stone JH, Grandi G, Pers JO, Specks U, Cornec D
Associated Clinical Trial(s):
Berti A, Hillion S, Konig MF, Moura MC, Hummel AM, Carmona E, Peikert T, Fervenza FC, Kallenberg CGM, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, Brunetta P, St Clair EW, Harris KM, Stone JH, Grandi G, Pers JO, Specks U, Cornec D (2023). Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol, 75(5), 736-747. https://doi.org/10.1002/art.42388 PMID: 36281741. PMCID: PMC10280646.
Allergen immunotherapy: past, present and future
Durham SR, Shamji MH
Associated Clinical Trial(s):
Durham SR, Shamji MH (2023). Allergen immunotherapy: past, present and future. Nat Rev Immunol, 23(5), 317-328. https://doi.org/10.1038/s41577-022-00786-1 PMID: 36253555. PMCID: PMC9575636.
Incorporating genetics in identifying peanut allergy risk and tailoring allergen immunotherapy: A perspective on the genetic findings from the LEAP trial
Huffaker MF, Kanchan K, Bahnson HT, Baloh C, Lack G, Nepom GT, Mathias RA
Associated Clinical Trial(s):
Huffaker MF, Kanchan K, Bahnson HT, Baloh C, Lack G, Nepom GT, Mathias RA (2023). Incorporating genetics in identifying peanut allergy risk and tailoring allergen immunotherapy: A perspective on the genetic findings from the LEAP trial. J Allergy Clin Immunol, 151(4), 841-847. https://doi.org/10.1016/j.jaci.2022.12.819 PMID: 36732171.
Recent progress in the genetic and epigenetic underpinnings of atopy
Baloh CH, Mathias RA
Associated Clinical Trial(s):
Baloh CH, Mathias RA (2023). Recent progress in the genetic and epigenetic underpinnings of atopy. J Allergy Clin Immunol, 151(1), 60-69. https://doi.org/10.1016/j.jaci.2022.10.027 PMID: 36608983. PMCID: PMC9987265.
Epitope-Specific IgE at 1 Year of Age Can Predict Peanut Allergy Status at 5 Years
Grinek S, Suprun M, Raghunathan R, Tomalin LE, Getts R, Bahnson T, Lack G, Sampson HA, Suarez-Farinas M
Associated Clinical Trial(s):
Grinek S, Suprun M, Raghunathan R, Tomalin LE, Getts R, Bahnson T, Lack G, Sampson HA, Suarez-Farinas M (2023). Epitope-Specific IgE at 1 Year of Age Can Predict Peanut Allergy Status at 5 Years. Int Arch Allergy Immunol, 184(3), 273-278. https://doi.org/10.1159/000526364 PMID: 36502801. PMCID: PMC9991938.
Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial
Corren J, Larson D, Altman MC, Segnitz RM, Avila PC, Greenberger PA, Baroody F, Moss MH, Nelson H, Burbank AJ, Hernandez ML, Peden D, Saini S, Tilles S, Hussain I, Whitehouse D, Qin T, Villarreal M, Sever M, Wheatley LM, Nepom GT, Sanda S, Immune Tolerance Network ITN057AD CATNIP Study Team
Associated Clinical Trial(s):
Corren J, Larson D, Altman MC, Segnitz RM, Avila PC, Greenberger PA, Baroody F, Moss MH, Nelson H, Burbank AJ, Hernandez ML, Peden D, Saini S, Tilles S, Hussain I, Whitehouse D, Qin T, Villarreal M, Sever M, Wheatley LM, Nepom GT, Sanda S, Immune Tolerance Network ITN057AD CATNIP Study Team (2023). Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial. J Allergy Clin Immunol, 151(1), 192-201. https://doi.org/10.1016/j.jaci.2022.08.029 PMID: 36223848. PMCID: PMC12205947.
Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy
Altman MC, Segnitz RM, Larson D, Jayavelu ND, Smith MT, Patel S, Scadding GW, Qin T, Sanda S, Steveling E, Eifan AO, Penagos M, Jacobson MR, Parkin RV, Shamji MH, Togias A, Durham SR
Associated Clinical Trial(s):
Altman MC, Segnitz RM, Larson D, Jayavelu ND, Smith MT, Patel S, Scadding GW, Qin T, Sanda S, Steveling E, Eifan AO, Penagos M, Jacobson MR, Parkin RV, Shamji MH, Togias A, Durham SR (2023). Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy. J Allergy Clin Immunol, 152(5), 1247-1260. https://doi.org/10.1016/j.jaci.2023.06.025 PMID: 37460024. PMCID: PMC10788383.
Early introduction of peanut reduces peanut allergy across risk groups in pooled and causal inference analyses
Logan K, Bahnson HT, Ylescupidez A, Beyer K, Bellach J, Campbell DE, Craven J, Du Toit G, Clare Mills EN, Perkin MR, Roberts G, van Ree R, Lack G
Associated Clinical Trial(s):
Logan K, Bahnson HT, Ylescupidez A, Beyer K, Bellach J, Campbell DE, Craven J, Du Toit G, Clare Mills EN, Perkin MR, Roberts G, van Ree R, Lack G (2023). Early introduction of peanut reduces peanut allergy across risk groups in pooled and causal inference analyses. Allergy, 78(5), 1307-1318. https://doi.org/10.1111/all.15597 PMID: 36435990. PMCID: PMC10202125.
Developing a Prediction Model for Determination of Peanut Allergy Status in the Learning Early About Peanut Allergy (LEAP) Studies
Sever ML, Calatroni A, Roberts G, du Toit G, Bahnson HT, Radulovic S, Larson D, Byron M, Santos AF, Huffaker MF, Wheatley LM, Lack G
Associated Clinical Trial(s):
Sever ML, Calatroni A, Roberts G, du Toit G, Bahnson HT, Radulovic S, Larson D, Byron M, Santos AF, Huffaker MF, Wheatley LM, Lack G (2023). Developing a Prediction Model for Determination of Peanut Allergy Status in the Learning Early About Peanut Allergy (LEAP) Studies. J Allergy Clin Immunol Pract, 11(7), 2217-2227.e9. https://doi.org/10.1016/j.jaip.2023.04.032 PMID: 37146884. PMCID: PMC11837399.
Omics-oriented research illustrated with the LEAP study and the OASIS bioinformatics tool
Baloh CH, Kanchan K, Shankar G, Nepom GT, Mathias RA, Perry JA
Associated Clinical Trial(s):
Baloh CH, Kanchan K, Shankar G, Nepom GT, Mathias RA, Perry JA (2023). Omics-oriented research illustrated with the LEAP study and the OASIS bioinformatics tool. J Allergy Clin Immunol, 151(2), 416-419. https://doi.org/10.1016/j.jaci.2022.12.003 PMID: 36521801.
In children with eczema, expansion of epitope-specific IgE is associated with peanut allergy at 5 years of age
Suprun M, Bahnson HT, du Toit G, Lack G, Suarez-Farinas M, Sampson HA
Associated Clinical Trial(s):
Suprun M, Bahnson HT, du Toit G, Lack G, Suarez-Farinas M, Sampson HA (2023). In children with eczema, expansion of epitope-specific IgE is associated with peanut allergy at 5 years of age. Allergy, 78(2), 586-589. https://doi.org/10.1111/all.15572 PMID: 36321870.
Defining the window of opportunity and target populations to prevent peanut allergy
Roberts G, Bahnson HT, Du Toit G, O'Rourke C, Sever ML, Brittain E, Plaut M, Lack G
Associated Clinical Trial(s):
Roberts G, Bahnson HT, Du Toit G, O'Rourke C, Sever ML, Brittain E, Plaut M, Lack G (2023). Defining the window of opportunity and target populations to prevent peanut allergy. J Allergy Clin Immunol, 151(5), 1329-1336. https://doi.org/10.1016/j.jaci.2022.09.042 PMID: 36521802. PMCID: PMC10689252.
IL-6-targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function
Speake C, Habib T, Lambert K, Hundhausen C, Lord S, Dufort MJ, Skinner SO, Hu A, Kinsman M, Jones BE, Maerz MD, Tatum M, Hocking AM, Nepom GT, Greenbaum CJ, Buckner JH
Associated Clinical Trial(s):
Speake C, Habib T, Lambert K, Hundhausen C, Lord S, Dufort MJ, Skinner SO, Hu A, Kinsman M, Jones BE, Maerz MD, Tatum M, Hocking AM, Nepom GT, Greenbaum CJ, Buckner JH (2022). IL-6-targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function. JCI Insight, 7(22). https://doi.org/10.1172/jci.insight.159436 PMID: 36282595. PMCID: PMC9746808.
A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes
Marwaha AK, Chow S, Pesenacker AM, Cook L, Sun A, Long SA, Yang JHM, Ward-Hartstonge KA, Williams E, Domingo-Vila C, Halani K, Harris KM, Tree TIM, Levings MK, Elliott T, Tan R, Dutz JP
Associated Clinical Trial(s):
Marwaha AK, Chow S, Pesenacker AM, Cook L, Sun A, Long SA, Yang JHM, Ward-Hartstonge KA, Williams E, Domingo-Vila C, Halani K, Harris KM, Tree TIM, Levings MK, Elliott T, Tan R, Dutz JP (2022). A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes. Immunother Adv, 2(1), ltab022. https://doi.org/10.1093/immadv/ltab022 PMID: 35072168. PMCID: PMC8769169.
Impact of Donor and Recipient Clinical Characteristics and Hepatic Histology on Steatosis/Fibrosis Following Liver Transplantation
Shaked O, Demetris J, Levitsky J, Feng S, Loza BL, Punch J, Reyes J, Klintmalm G, Jackson W, DesMarais M, Sayre P, Shaked A, Reddy KR
Associated Clinical Trial(s):
Shaked O, Demetris J, Levitsky J, Feng S, Loza BL, Punch J, Reyes J, Klintmalm G, Jackson W, DesMarais M, Sayre P, Shaked A, Reddy KR (2022). Impact of Donor and Recipient Clinical Characteristics and Hepatic Histology on Steatosis/Fibrosis Following Liver Transplantation. Transplantation, 106(1), 106-116. https://doi.org/10.1097/TP.0000000000003681 PMID: 33982909. PMCID: PMC8349377.
Standardizing the histological assessment of late posttransplantation biopsies from pediatric liver allograft recipients
Hübscher SG, Feng S, Gouw ASH, Haga H, Kang HJ, Kelly DA, Komuta M, Lesniak A, Popp BA, Verkade HJ, Yu E, Demetris AJ
Associated Clinical Trial(s):
Hübscher SG, Feng S, Gouw ASH, Haga H, Kang HJ, Kelly DA, Komuta M, Lesniak A, Popp BA, Verkade HJ, Yu E, Demetris AJ (2022). Standardizing the histological assessment of late posttransplantation biopsies from pediatric liver allograft recipients. Liver Transpl, 28(9), 1475-1489. https://doi.org/10.1002/lt.26482 PMID: 35429359.
Graft Fibrosis Over 10 to 15 Years in Pediatric Liver Transplant Recipients: Multicenter Study of Paired, Longitudinal Surveillance Biopsies
Perito ER, Persyn E, Bucuvalas J, Martinez M, Mohammad S, Squires JE, Demetris AJ, Feng S
Associated Clinical Trial(s):
Perito ER, Persyn E, Bucuvalas J, Martinez M, Mohammad S, Squires JE, Demetris AJ, Feng S (2022). Graft Fibrosis Over 10 to 15 Years in Pediatric Liver Transplant Recipients: Multicenter Study of Paired, Longitudinal Surveillance Biopsies. Liver Transpl, 28(6), 1051-1062. https://doi.org/10.1002/lt.26409 PMID: 35029022.
Selective decrease of donor-reactive T(regs) after liver transplantation limits T(reg) therapy for promoting allograft tolerance in humans
Tang Q, Leung J, Peng Y, Sanchez-Fueyo A, Lozano JJ, Lam A, Lee K, Greenland JR, Hellerstein M, Fitch M, Li KW, Esensten JH, Putnam AL, Lares A, Nguyen V, Liu W, Bridges ND, Odim J, Demetris AJ, Levitsky J, Taner T, Feng S
Associated Clinical Trial(s):
Tang Q, Leung J, Peng Y, Sanchez-Fueyo A, Lozano JJ, Lam A, Lee K, Greenland JR, Hellerstein M, Fitch M, Li KW, Esensten JH, Putnam AL, Lares A, Nguyen V, Liu W, Bridges ND, Odim J, Demetris AJ, Levitsky J, Taner T, Feng S (2022). Selective decrease of donor-reactive T(regs) after liver transplantation limits T(reg) therapy for promoting allograft tolerance in humans. Sci Transl Med, 14(669), eabo2628. https://doi.org/10.1126/scitranslmed.abo2628 PMID: 36322627. PMCID: PMC11016119.
Ex vivo generation of regulatory T cells from liver transplant recipients using costimulation blockade
Shimozawa K, Contreras-Ruiz L, Sousa S, Zhang R, Bhatia U, Crisalli KC, Brennan LL, Turka LA, Markmann JF, Guinan EC
Associated Clinical Trial(s):
Shimozawa K, Contreras-Ruiz L, Sousa S, Zhang R, Bhatia U, Crisalli KC, Brennan LL, Turka LA, Markmann JF, Guinan EC (2022). Ex vivo generation of regulatory T cells from liver transplant recipients using costimulation blockade. Am J Transplant, 22(2), 504-518. https://doi.org/10.1111/ajt.16842 PMID: 34528383. PMCID: PMC9078620.
Synergistic targeting of immunologic pathways to empower durable tolerance therapies
Nepom GT
Associated Clinical Trial(s):
Nepom GT (2022). Synergistic targeting of immunologic pathways to empower durable tolerance therapies. Front Immunol, 13, 962177. https://doi.org/10.3389/fimmu.2022.962177 PMID: 36119087. PMCID: PMC9478166.
Stabilization of leukocytes from cerebrospinal fluid for central immunophenotypic evaluation in multicenter clinical trials
Mexhitaj I, Lim N, Fernandez-Velasco JI, Zrzavy T, Harris KM, Muraro PA, Villar LM, Bar-Or A, Cooney LA
Associated Clinical Trial(s):
Mexhitaj I, Lim N, Fernandez-Velasco JI, Zrzavy T, Harris KM, Muraro PA, Villar LM, Bar-Or A, Cooney LA (2022). Stabilization of leukocytes from cerebrospinal fluid for central immunophenotypic evaluation in multicenter clinical trials. J Immunol Methods, 510, 113344. https://doi.org/10.1016/j.jim.2022.113344 PMID: 36041516.
